Therapeutic or Preventive Procedure – Page 110

Day One Outshines Novartis: FDA Approves Ojemda for Wider Pediatric Brain Tumor Treatment

2 years ago talkbio0Tagged Brain Neoplasms, Cancer Therapeutic Procedure, Clinical Trials, Drug Industry, Novartis, Ojemda, Pediatric brand name, United States Food and Drug Administration

Day One, Novartis, FDA, Ojemda, pediatric brain tumor, cancer treatment, clinical trials, pharmaceutical industry.

BMS-Cellares Collaboration Spotlights U.S.-China Biopharma Rivalry

2 years ago talkbio0Tagged Biopharma, Burning Mouth Syndrome, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Cellares, Collaboration, rivalry, Tension, U.S.-China

BMS, Cellares, CAR-T, collaboration, U.S.-China tensions, biopharma rivalry, cell therapy, cancer treatment.

ImmunityBio’s Anktiva Receives FDA Approval, Set to Rival Merck in Bladder Cancer Treatment

2 years ago talkbio0Tagged Anktiva, Approved, Cancer Therapeutic Procedure, ImmunityBio, Malignant neoplasm of urinary bladder, United States Food and Drug Administration

ImmunityBio, Anktiva, FDA approval, bladder cancer, Merck, cancer treatment, Patrick Soon-Shiong.

FDA Grants Approval to ImmunityBio’s Innovative Combination Therapy for Bladder Cancer

2 years ago talkbio0Tagged Approved, Clinical Trials, Combined Modality Therapy, ImmunityBio, Immunotherapy, Malignant neoplasm of urinary bladder, United States Food and Drug Administration

FDA, ImmunityBio, bladder cancer, combination therapy, approval, innovative treatment, immunotherapy, clinical trials

FDA Issues Complete Response Letter to Abeona’s Cell Therapy for Rare Skin Disease

2 years ago talkbio0Tagged Abeona, Cell Therapy, Complete, CRL, Dermatologic disorders, Epidermolysis Bullosa, Infrequent, United States Food and Drug Administration

FDA, Complete Response Letter (CRL), Abeona, cell therapy, rare skin disease, Epidermolysis Bullosa (EB)

Incyte Expands Portfolio with $750 Million Acquisition of Escient, a Pioneer in Immune and Neuro Biotechnology

2 years ago talkbio0Tagged Acquisition (action), Biotechnology, Drug Development, Escient, expansion, G-Protein-Coupled Receptors, Immune system, Incyte, Neuroscience discipline, portfolio, targets

Incyte, Escient, biotechnology, immune system, neuroscience, acquisition, deal, $750 million, portfolio expansion, drug development, therapeutics, GPCR targets.

ImmunityBio’s Innovative IL-15 Superagonist Receives FDA Approval for Non-Muscle Invasive Bladder Cancer Treatment

2 years ago talkbio0Tagged Approved, Carcinoma of urinary bladder, invasive, ImmunityBio, Immunotherapy, Interleukin-15, Malignant Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Superagonist, United States Food and Drug Administration

ImmunityBio, FDA Approval, IL-15 Superagonist, Non-Muscle Invasive Bladder Cancer (NMIBC), Immunotherapy, Cancer Treatment

Boehringer Ingelheim and Ochre Bio Join Forces in a $1 Billion Collaboration to Combat Chronic Liver Diseases

2 years ago2 years ago talkbio0Tagged boehringer ingelheim, Chronic liver disease, Collaboration, Drug Discovery, Fibrosis, Liver, Nonalcoholic Steatohepatitis, RNA

Boehringer Ingelheim, Ochre Bio, collaboration, chronic liver diseases, $1 billion, drug discovery, RNA therapeutics, liver fibrosis, non-alcoholic steatohepatitis (NASH)

BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares

2 years ago talkbio0Tagged Automation, Biotechnology, Burning Mouth Syndrome, Cancer Therapeutic Procedure, Capacity, CAR-T, Cell Therapy, Cellares, expansion, Investments, Manufacture, squibb

BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.

Ipsen and Skyhawk Therapeutics Join Forces in a $1.8 Billion Deal to Advance RNA Modulator Research

2 years ago talkbio0Tagged Biological Factors, development aspects, Drug Discovery, Ipsen, Partnership, R&D, RNA modulators, Skyhawk

Ipsen, Skyhawk Therapeutics, RNA modulators, drug discovery, partnership, $1.8 billion, biopharmaceutical, R&D, therapeutic development